TP53 and myelodysplastic syndrome: In MDS and AML, p53 protein inactivation and TP53 gene mutations represent a clinically important predictive biomarker to DNA damaging chemotherapy [37] or venetoclax [38, 39] and are thus, underlying adverse prognoses which may dependent on complex karyotype.